Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. D. Boral Capital’s price objective would suggest a potential upside of 412.98% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Stock Performance

Shares of NASDAQ:HOTH opened at $0.97 on Monday. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The business’s 50 day simple moving average is $1.11 and its two-hundred day simple moving average is $1.01. The firm has a market cap of $6.73 million, a P/E ratio of -0.74 and a beta of 0.84.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. On average, equities analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics at the end of the most recent quarter. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.